Innovus Pharmaceuticals, Inc. (OTCQB: INNV), a La Jolla-based commercial stage pharmaceutical company that makes over-the-counter medicine and consumer care products, announced the company was added to OTCQB Venture Index.
The OTCQB Index is designed as a benchmark for tracking the overall performance of the OTCQB marketplace and serves primarily as a performance benchmark for investors in OTCQB securities. The index highlights entrepreneurial and development stage U.S. and international companies that have been verified to trade on OTCQB.
The addition of Innovus to the OTCQB Venture Index due to its increased trading volume and liquidity will enhance the company's visibility with investors as the OTCQB is under a stricter market standards and eligibility requirements.
Bassam Damaj, president and CEO of Innovus Pharma, said, "We are extremely pleased that Innovus has been added to the OTCQB Venture Index. We believe the increased trading volume and liquidity of the stock is a very good sign of the company's growing acceptance in the marketplace among investors, leading to its addition to this Index. In addition, the Company is working diligently to uplist to a higher exchange such as the NYSE or NASDAQ."